The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease
NCT02231294 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1464
Last updated 2014-09-04
Summary
Documentation of the effect of SIFROL® on tremor and depression as well as its tolerability in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions
Conditions
- Parkinson Disease
Interventions
- DRUG
-
Sifrol®
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-07-31
- Primary Completion
- 2002-01-31
More Related Trials
-
Long-term Administration Study of SND 919 Tablets in Parkinson's Disease
NCT00274131 ·Status: COMPLETED ·Phase: PHASE3
-
Improving Quality of Life in Early Parkinson's Disease
NCT04590612 ·Status: UNKNOWN ·Phase: NA
-
A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
NCT03531060 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
NCT02565628 ·Status: COMPLETED ·Phase: PHASE1
-
Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease
NCT02162979 ·Status: TERMINATED ·Phase: PHASE2
-
Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease
NCT02231905 ·Status: COMPLETED ·Phase: PHASE4
-
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
NCT00148486 ·Status: COMPLETED ·Phase: PHASE2
-
Istradefylline Effect Protocol on Parkinson's Disease Tremor
NCT05885360 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase II Safety and Tolerability Study With SEN0014196
NCT01521585 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
NCT02224664 ·Status: COMPLETED ·Phase: PHASE1
-
EMD 128130 for the Treatment of Parkinson's Disease
NCT00009048 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Antidepressants in Parkinson's Disease
NCT00086190 ·Status: COMPLETED ·Phase: PHASE3
-
Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease
NCT00921128 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
NCT06873334 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Study to Evaluate SYN115 in Parkinson's Disease
NCT00605553 ·Status: COMPLETED ·Phase: PHASE2
-
Cilostazol in Parkinson's Disease
NCT06612593 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients
NCT02073981 ·Status: COMPLETED
-
Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease
NCT00228150 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease
NCT05931575 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Examine APL-130277 in Patients With Parkinson's Disease
NCT02228590 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
NCT02157714 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
NCT06822517 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Idebenone Treatment of Early Parkinson's Diseasesymptoms
NCT03727295 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
NCT00163085 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
NCT02373072 ·Status: COMPLETED ·Phase: PHASE1